DEERFIELD, Ill., June 24 Astellas Pharma US, Inc. todayannounced the commercial availability of Lexiscan(TM) (regadenoson) injection,an A2A adenosine receptor agonist, for use as a pharmacologic ...
In a patent battle with Pfizer's generic unit Hospira, Astellas is trying to extend the exclusivity of its imaging product Lexiscan. (Christian Richters/View Pictures/Universal Images Group via Getty ...
WASHINGTON, Nov. 20 (UPI) -- The U.S. Food and Drug Administration warns doctors of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents. The cardiac ...
WESTON, Fla. – After his sister underwent surgery for a pacemaker, Ken Wurtenberg worried about his own heart. When an electrocardiogram and echocardiogram came back irregular, his doctor recommended ...
"We are extremely pleased that the FDA has approved Lexiscan, an exciting new option for diagnosing coronary artery disease in patients who cannot undergo an exercise stress test," said Yoshihiko ...
This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. May 13, ...
Please provide your email address to receive an email when new articles are posted on . The FDA has issued a safety announcement warning health care professionals of rare but serious risk for MI and ...
Hyderabad: Dr. Reddy's Laboratories Ltd. (Dr Reddy's), announced the launch of Regadenoson Injection in the US market. The injection is the generic therapeutic equivalent of the US Food and Drug ...
The U.S. Food and Drug Administration warned physicians on Wednesday that two chemicals used to conduct cardiovascular stress tests can cause heart attacks and death, and it suggested resuscitation ...
PALO ALTO, Calif. and DEERFIELD, Ill., April 10 -- CV Therapeutics and Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lexiscan(TM) (regadenoson) ...
"We are extremely pleased that the FDA has approved Lexiscan, an exciting new option for diagnosing coronary artery disease in patients who cannot undergo an exercise stress test," said Yoshihiko ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results